Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.
Phase of Trial: Phase II
Latest Information Update: 16 May 2016
At a glance
- Drugs Lapatinib (Primary) ; Letrozole
- Indications Early breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms LET-LOB
- 04 Jun 2013 Biomarker results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jul 2011 Preliminary results have been reported at ASCO 2011.
- 01 Apr 2011 Primary endpoint 'Objective-clinical-response-rate' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History